{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:44:19Z","timestamp":1792842259401,"version":"4.5.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T00:00:00Z","timestamp":1628899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s40265-021-01578-y","type":"journal-article","created":{"date-parts":[[2021,8,14]],"date-time":"2021-08-14T09:02:42Z","timestamp":1628931762000},"page":"1593-1596","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Upacicalcet: First Approval"],"prefix":"10.1007","volume":"81","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,8,14]]},"reference":[{"key":"1578_CR1","doi-asserted-by":"publisher","unstructured":"Ketteler M, Ambuhl P. Where are we now? Emerging opportunities and challenges in the management of secondary hyperparathyroidism in patients with non-dialysis chronic kidney disease. J Nephrol. 2021. https:\/\/doi.org\/10.1007\/s40620-021-01082-2.","DOI":"10.1007\/s40620-021-01082-2"},{"issue":"4","key":"1578_CR2","doi-asserted-by":"publisher","first-page":"913","DOI":"10.2215\/CJN.06040710","volume":"6","author":"J Cunningham","year":"2011","unstructured":"Cunningham J, Locatelli F, Rodriguez M. Secondary hyperparathyroidism: pathogenesis, disease progression, and therapeutic options. Clin J Am Soc Nephrol. 2011;6(4):913\u201321.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"7","key":"1578_CR3","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s11255-018-1838-5","volume":"50","author":"M Rroji","year":"2018","unstructured":"Rroji M, Spasovski G. Calcimimetics versus parathyroidectomy: what is preferable? Int Urol Nephrol. 2018;50(7):1271\u20135.","journal-title":"Int Urol Nephrol"},{"issue":"4","key":"1578_CR4","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s00223-020-00788-y","volume":"108","author":"H Komaba","year":"2021","unstructured":"Komaba H, Ketteler M, Cunningham J, et al. Old and new drugs for the management of bone disorders in CKD. Calcif Tissue Int. 2021;108(4):486\u201395.","journal-title":"Calcif Tissue Int"},{"key":"1578_CR5","unstructured":"Kissei Pharmaceutical Co. Ltd. Announcement of Marketing Authorization Approval in Japan and co-promotion agreement of UPASITA\u00ae IV injection syringe for the treatment of secondary hyperparathyroidism in dialysis patients [media release]. 23 Jun 2021. https:\/\/www.kissei.co.jp."},{"key":"1578_CR6","unstructured":"Sanwa Kagaku Kenkyusho Co Ltd. Sanwa Kagaku Kenkyusho Co Ltd.: company presentation (March 2018). 2018. https:\/\/www.een-japan.eu\/sites\/default\/files\/PSEU-Japanese_POD\/SanwaKagakuKenkyusho\/BIO-Europe_Spring_2018_SKK_Company_Presentation.pdf. Accessed 8 Jul 2021."},{"key":"1578_CR7","unstructured":"EA Pharma, Tasly Pharmaceutical Group. Signed license agreement with Chinese Tasly Pharmaceutical Group of AJT 240 for treatment of secondary hyperparathyroidism [media release]. 12 Jun 2018. http:\/\/www.eapharma.co.jp."},{"key":"1578_CR8","volume-title":"UPASITA\u00ae IV injection syringe for dialysis: Japanese prescribing information","author":"Sanwa Kagaku Kenkyusho Co Ltd","year":"2021","unstructured":"Sanwa Kagaku Kenkyusho Co Ltd. UPASITA\u00ae IV injection syringe for dialysis: Japanese prescribing information. Nagoya: Sanwa Kagaku Kenkyusho Co Ltd; 2021."},{"key":"1578_CR9","unstructured":"EA Pharma. EA Pharma signed a license agreement with JW Pharmaceutical for secondary hyperparathyroidism treatment AJT240 [media release]. 31 Oct 2017. http:\/\/www.eapharma.co.jp."},{"key":"1578_CR10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1681\/ASN.20203110S1148b","volume":"31","author":"G Nishimura","year":"2020","unstructured":"Nishimura G, Yamaguchi Y, Goto M, et al. Upacicalcet, a novel non-peptide calcimimetic for the treatment of secondary hyperparathyroidism, has a low risk of hypocalcemia [abstract no. PO0318]. J Am Soc Nephrol. 2020;31:148.","journal-title":"J Am Soc Nephrol"},{"key":"1578_CR11","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1681\/ASN.2019111183","volume":"31","author":"T Akizawa","year":"2020","unstructured":"Akizawa T, Honda D, Taniguchi M, et al. Efficacy and safety of upacicalcet in hemodialysis patients with secondary hyperparathyroidism: a phase 3 study [abstract no. TH-OR20]. J Am Soc Nephrol. 2020;31:6\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"1578_CR12","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT03801980. 2020. http:\/\/clinicaltrials.gov\/. Accessed 9 Jul 2021."},{"key":"1578_CR13","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT03626948. 2020. http:\/\/clinicaltrials.gov\/. Accessed 9 Jul 2021."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01578-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-021-01578-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-021-01578-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,6]],"date-time":"2024-09-06T14:07:31Z","timestamp":1725631651000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-021-01578-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,14]]},"references-count":13,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["1578"],"URL":"https:\/\/doi.org\/10.1007\/s40265-021-01578-y","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,14]]},"assertion":[{"value":"14 August 2021","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. S. M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}